Trending Similar Videos
Drug pricing initiatives during the Trump presidency
Tom Bulleit, Ropes & Gray health care partner, discusses the Trump Administration’s latest drug pricing initiatives.
New anti-abuse provisions
Kat Saunders Gregor, Ropes & Gray tax partner and co-founder of the tax controversy group, examines the influx of new anti-abuse provisions around the world.
Active nontransparent ETFs
Brian McCabe, Ropes & Gray asset management partner, discusses active nontransparent ETFs and the opportunities they offer to investors and asset managers of traditional mutual funds.
Section 101: confusion over patentable subject matter
Matt Rizzolo, Ropes & Gray IP litigation partner, addresses the ongoing confusion over what constitutes patentable subject matter under Section 101 of the Patent Act.
Behavioral sciences approach to risk management
Amanda Raad, co-chair of Ropes & Gray’s anti-corruption & international risk practice, discusses the new data-driven behavioral sciences approach to risk management.
Impact of changes at the PTAB on patent owners
Scott McKeown, Ropes & Gray IP litigation partner and chair of the firm’s Patent Trial and Appeal Board (PTAB) group, examines how some recent changes at the PTAB will benefit patent owners.